Apr 30, 2018 - Technology

Gilead, Alphabet's Verily team up on immune cell research

A biologist studies immune cells in a lab. Photo: Saul Loeb/AFP via Getty Images

Gilead Sciences is contracting with Verily Life Sciences, part of Alphabet and a sister company to Google, to research immune cells in the hopes of finding new treatments for rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases.

Why it matters: Gilead has several drug candidates in the works that go after these diseases, and the drug giant is making a bet that Verily can get them across the finish line. Meanwhile, Forbes pegged the deal at $90 million over three years.

Go deeper

Axios
Updated 28 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Economy: Why the stimulus delay isn't a crisis (yet).
  3. Health: The pandemic is getting worse again — New York reports most cases since May —Many U.S. coronavirus deaths were avoidable.
  4. Education: Boston and Chicago send students back home for online learning.
  5. World: Spain becomes first nation in Western Europe to exceed 1 million cases — France becomes the second.
Go deeper (1 min. read)Arrow
Axios
44 mins ago - Politics & Policy

Biden says he will appoint commission on Supreme Court reform

Photo: Chip Somodevilla/Getty Images

Joe Biden told CBS' "60 Minutes" this week that if elected, he would put together a bipartisan commission to study the federal court system and make recommendations for reform.

Why it matters: Biden has come under pressure to clarify his position on court packing after some Democrats suggested expanding the court if Senate Republicans confirm President Trump's Supreme Court nominee Amy Coney Barrett.

Go deeper (1 min. read)Arrow
Dion Rabouin, author of Markets
59 mins ago - Economy & Business

Wall Street still prefers bonds

Illustration: Aïda Amer/Axios. Photo: Sunset Boulevard/Getty Contributor

Investors' return on U.S. corporate bonds has been falling since its August peak, but buying has only accelerated, especially in investment grade bonds that are offering historically low yields.

The state of play: Since hitting its 2020 high on Aug. 4, the benchmark Bloomberg Barclays U.S. bond aggregate has delivered a -2.2% return. (For comparison, the S&P 500 has gained 3.9% during the same time period.)

Go deeper (3 min. read)Arrow